Abstract 19680: Prognostic Utility of Growth Hormone for All-Cause and Cardiovascular Mortality in a United States National Cohort of Black and White Adults
Introduction: Elevated growth hormone (GH) levels are associated with a higher incidence of cardiovascular (CV) morbidity and mortality. Despite gender differences in GH levels, the impact of gender on the association of GH levels and CV mortality has not been investigated.
Hypothesis: We hypothesized that gender influences prognostic value of GH.
Methods: The REasons for Geographic and Racial Disparities in Stroke (REGARDS) study enrolled 30,239 black and white individuals aged 45 years and older. A stratified case-cohort study design with 1,046 randomly selected participants was used. Fasting GH levels were measured and evaluated for outcomes of all-cause and CV mortality. Outcomes were assessed by gender and in multivariable analyses.
Results: Women had higher fasting GH levels compared to men (0.46 [0.17-1.12] vs. 0.13 [0.05-0.48], p<0.0001). GH was associated with all-cause mortality in the entire cohort (hazard ratio (HR) 1.7, 95% CI 1.3-2.2, p=0.0004) and in men (HR 2.2, 95% CI 1.6- 3.0, p<0.0001), but not women (HR 1.2, 95% CI 0.8-1.7, p= 0.3659). Similarly, GH was associated with CV mortality in the entire cohort (HR 2.3, 95% CI 1.3-4.0, p= 0.0041) and in men (HR 2.4, 95% CI 1.3- 4.4, p= 0.0034), but not in in women (HR 1.7, 95% CI 0.7-3.8, p= 0.2068) (table 1). When analyzed by GH quartiles, men had higher all-cause and CV mortality with increasing quartile (figure 1).
Conclusions: GH is predictive of all-cause and CV mortality only in men, potentially representing a specific biomarker for risk stratification of cardiovascular disease in men.
Author Disclosures: R. Mital: None. N. Wettersten: None. O. Hartmann: Employment; Significant; Statistician for SphingoTec. M. Cushman: Research Grant; Modest; Funding for Diadexus. V.J. Howard: None. G. Filippatos: None. G. Howard: None. M.M. Safford: Research Grant; Significant; Amgen Inc. Consultant/Advisory Board; Modest; diaDexus. S.E. Judd: None. A. Bergmann: Employment; Significant; President of SphingoTec. J. Struck: Employment; Significant; Head of research and development at SphingoTec. A. Maisel: None.
- © 2016 by American Heart Association, Inc.